Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mycenax BiotechROCO:4726 -0.62%47 Piotroski F-Score is 7 as of Sep. 01, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates ROCO:4726 with a GF Score™ of 47/100 and a GF Value™ of NT$46.67 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,339 Biotechnology companies, Mycenax Biotech ranks better than 96.94% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Mycenax Biotech has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Mycenax Biotech's Piotroski F-Score or its related term are showing as below:
ROCO:4726'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 8
Current: 7
During the past 13 years, the highest Piotroski F-Score of Mycenax Biotech was 8. The lowest was 1. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Mycenax Biotech Piotroski F-Score Related Terms
Mycenax Biotech Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Mycenax Biotech's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4726 vs VRTX, REGN, MRNA: Piotroski F-Score Comparison
For the Biotechnology subindustry, Mycenax Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mycenax Biotech Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mycenax Biotech's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Mycenax Biotech's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun26) TTM:
Last Year (Jun25) TTM:
Net Income was -129.879 + -52.449 + -116.986 + -82.593 = NT$-381.9 Mil. Cash Flow from Operations was -50.346 + 87.36 + -26.021 + 111.686 = NT$122.7 Mil. Revenue was 131.371 + 284.592 + 196.814 + 203.093 = NT$815.9 Mil. Gross Profit was -65.256 + 5.005 + -59.065 + -18.367 = NT$-137.7 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(3214.921 + 3329.027 + 3261.245 + 3343.414 + 3279.204) / 5 = NT$3285.5622 Mil. Total Assets at the begining of this year (Jun25) was NT$3,214.9 Mil. Long-Term Debt & Capital Lease Obligation was NT$438.9 Mil. Total Current Assets was NT$870.3 Mil. Total Current Liabilities was NT$1,432.2 Mil.
Net Income was -146.612 + -83.286 + -129.137 + -137.162 = NT$-496.2 Mil.
Revenue was 209.13 + 193.993 + 121.716 + 202.559 = NT$727.4 Mil. Gross Profit was -68.857 + -35.269 + -78.497 + -42.664 = NT$-225.3 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(3630.819 + 3477.766 + 3368.376 + 3339.409 + 3214.921) / 5 = NT$3406.2582 Mil. Total Assets at the begining of last year (Jun24) was NT$3,630.8 Mil. Long-Term Debt & Capital Lease Obligation was NT$606.6 Mil. Total Current Assets was NT$706.1 Mil. Total Current Liabilities was NT$841.5 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Mycenax Biotech's current Net Income (TTM) was -381.9.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Mycenax Biotech's return on assets of this year was -0.11879203. Mycenax Biotech's return on assets of last year was -0.13666255.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Mycenax Biotech's gearing of this year was 0.13359175. Mycenax Biotech's gearing of last year was 0.17806988.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Mycenax Biotech's current ratio of this year was 0.6076352. Mycenax Biotech's current ratio of last year was 0.8390372.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Mycenax Biotech's number of shares in issue this year was 206.483. Mycenax Biotech's number of shares in issue last year was 207.821.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Mycenax Biotech's gross margin of this year was -0.16875605. Mycenax Biotech's gross margin of last year was -0.30971628.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Mycenax Biotech's asset turnover of this year was 0.25377606. Mycenax Biotech's asset turnover of last year was 0.20033992.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
1
+
1
+
1
+
0
+
1
+
1
+
1
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Mycenax Biotech has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Mycenax Biotech (ROCO:4726) has a Piotroski F-Score of 7 as of Sep. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Mycenax Biotech and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, Mycenax Biotech's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Mycenax Biotech ranks #41 out of 1339 companies in the Biotechnology industry, placing it in the top 3.1%.
Is Mycenax Biotech's Piotroski F-Score too high?
Mycenax Biotech's current Piotroski F-Score of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Mycenax Biotech's value of 7 is 133.3% above this industry median. Based on the distribution chart, Mycenax Biotech ranks #41 out of 1339 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mycenax Biotech has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mycenax Biotech's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mycenax Biotech ranks #41 out of 1339 companies for Piotroski F-Score. This places Mycenax Biotech in the top 3% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Mycenax Biotech's value of 7 is 133.3% above this benchmark. Historically, Mycenax Biotech's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Mycenax Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,339 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mycenax Biotech's current Piotroski F-Score of 7 is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Mycenax Biotech and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mycenax Biotech's current Piotroski F-Score is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mycenax Biotech stock overvalued right now?
Based on GuruFocus' analysis, Mycenax Biotech (ROCO:4726) is currently considered Possible Value Trap. The stock's GF Value™ is NT$46.67, compared to a current price of NT$24.05 — trading 48.5% below its estimated fair value. The current Piotroski F-Score is 7, which is 75% above median its 10-year median of 4.00 and 133.3% above the Biotechnology industry median of 3.00. Mycenax Biotech's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Mycenax Biotech (ROCO:4726), the current Piotroski F-Score is 7 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mycenax Biotech (ROCO:4726) Overvalued in 2026?
Based on GuruFocus' analysis, Mycenax Biotech stock appears to be undervalued.
The current stock price of NT$24.05 is trading 48.5% below its estimated GF Value™ of NT$46.67.
GuruFocus considers Mycenax Biotech to be Possible Value Trap.
Key valuation signals for ROCO:4726:
Piotroski F-Score: 7 (75% above median its 10-year median of 4.00)
GF Value™: NT$46.67 vs. price of NT$24.05 (48.5% below fair value)
Industry Position: 133.3% above the Biotechnology median (#41 of 1339)
No single metric tells the full story. See the ROCO:4726 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.
47GF Score
Get the complete analysis for ROCO:4726
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4726 has been successfully added to your 
